ORIC Pharmaceuticals has received FDA approval for the first clinical trial of ORIC-533. It is an inhibitor of the substance CD-73, which controls the rate of creation of extracellular adenosine, which can improve the effectiveness of chemotherapy and immunotherapy. Phase I clinical trials of ORIC-533 are scheduled to begin in the second half of 2021.
ORIC Pharmaceuticals has received FDA approval for the first clinical trial of ORIC-533. It is an inhibitor of the substance CD-73, which controls the rate of creation of extracellular adenosine, which can improve the effectiveness of chemotherapy and immunotherapy. Phase I clinical trials of ORIC-533 are scheduled to begin in the second half of 2021. 
investors.oricpharma.com
English (US) 